They have an increased prescription of
neuroleptics and anti-depressants, which indicates that anxiety and depression are over-represented in people with haemophilia.
The third hypothesis involves hyperactivity of the sympathetic nervous system; it is thought that psychologic stressors alter frontal lobe function, with
neuroleptics disrupting the inhibitory pathways of the sympathetic nervous system.
Neuroleptic malignant syndrome (NMS) has been conceptualized as an iatrogenic form of malignant catatonia secondary to antipsychotic use (see Table 1) [1].
A high degree of suspicion must be maintained for any surgical patient taking shortterm or longterm
neuroleptics because, despite its rarity, NMS is potentially fatal.
Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal idiosyncratic reaction to
neuroleptics, characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia (1).
Hyperthermia, diaphoresis, sialorrhea, akinetic-hypertonic syndrome, stupor, dyspnoea, blood pressure oscillations and oniric confusion syndrome are only some of the symptoms requiring careful supervision in a specialized medical unit, symptomatic treatment and cessation of
neuroleptic medication (2, 3, 4).
Moreover, we compared in two different analyses patients on atypical
neuroleptics monotherapy versus patients with a second atypical
neuroleptic in add-on and patients with atypical
neuroleptics monotherapy versus patients with haloperidol in add-on, with the Mann-Whitney Test.
The
Neuroleptic Malignant Syndrome (NMS) is a medical emergency of rare presentation in a service.
Neuroleptic Malignant Syndrome (NMS) is an idiosyncratic and potentially life-threatening reaction to
neuroleptic drugs.
As Tardive dyskinesia is frequently associated with first generation
neuroleptics, these medications should be used restrictively only in major mental disorder and also doses should be kept low.
Given that treatments for AD and DLB are mostly supportive, this scale is unlikely to change clinical practice dramatically except for alerting physicians that a trial of movement-facilitating therapies such as levodopa/carbidopa and aggressive physical therapy is indicated, and that standard
neuroleptics should be avoided.
(19) Olmsted has suggested the following guidelines for administration of
neuroleptics after NMS resolution.
